Truffle Capital
Truffle Capital is a Paris-based VC with strong focus on therapeutics and interventional medtech. We often start companies from academic research sourced in the US or Europe then grow them until late clinical trials or commercial stage.
Our biotech portfolio includes:
Abivax (NASDAQ: ABVX): Lead drug candidate, obefazimod (ABX464) in Phase 3 for the treatment of moderately to severely active ulcerative colitis.
SpikImm: spin-off from Institut Pasteur that develops prophylactic, long-acting mAbs to protect immunocompromised patients, including kidney transplant recipients from viral infections such as BK virus
Evexta Bio: spin-off from Merck KGaA, Phase 2-ready first-in-class oral dual S6K & AKT1/3 inhibitor in ER+ HER2- advanced or metastatic breast cancer with ESR1 mutations
PKMed develops PKM-01, a phase 2-ready local intra-articular injection treatment for gout flares, aiming to provide a fast and effective pain relief and powerful and safe anti-inflammatory effect
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}